Oaktree Acquisition CORP Iii Life Sciences 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences files its Q2 2026 10-Q, reporting net income driven by interest income and detailing its ongoing search for a business combination target.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences reports net income of $1.39 million for Q1 2026, driven by trust account interest, while continuing its search for a business combination.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences reported a net income of $1.97 million for Q3 2025, driven by trust account interest, but faces substantial doubt about its ability to continue as a going concern.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported a net income of $1.87 million for Q2 2025, primarily from trust account interest, as it continues its search for a business combination target.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences reports a net income of $1.66 million for the quarter ended March 31, 2025, driven by interest earned on cash held in trust.